Project: Every Child for Younger Patients With Cancer

ConditionsAdrenal Gland Pheochromocytoma Carcinoma In Situ Central Nervous System Neoplasm Childhood Immature Teratoma Childhood Kidney Neoplasm Childhood Langerhans Cell Histiocytosis Childhood Mature Teratoma Congenital Mesoblastic Nephroma Desmoid Fibromatosis Ganglioneuroma Lymphoproliferative Disorder Malignant Neoplasm Malignant Solid Neoplasm Melanocytic Neoplasm Myeloproliferative Neoplasm Neoplasm of Uncertain Malignant Potential Neuroendocrine Neoplasm Stromal Neoplasm

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

AgeUp to 25

SponsorChildren's Oncology Group

About this trial

This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Enrollment must occur within 6 months of initial disease presentation OR within 6 months of refractory disease, disease progression, disease recurrence, second or secondary malignancy, or post-mortem

Patients previously enrolled on ACCRN07 are eligible to enroll on Tracking Outcome, Registry and Future Contact components of APEC14B1 any time after they reach age of majority

All cancer cases with an International Classification of Diseases for Oncology (ICD-O) histologic behavior code of one "1" (borderline), two "2" (carcinoma in situ) or three "3" (malignant)

All neoplastic lesions of the central nervous system regardless of behavior, i.e., benign, borderline or malignant

Disqualifiers

None

Trial population

Patients with cancer enrolled on COG therapeutic study

Trial design

Design model

Other

Time perspective

Other

Treatments tested in this trial

Cytology Specimen Collection Procedure
Other intervention
Undergo cytology specimen collection
Medical Chart Review
Other intervention
Undergo medical data review

Treatment groups

75,000 Participants

are divided into 2 treatment groups

Group A: Observational Project AYA Protocol1 intervention

Group B: Observational Project: Every Child Protocol2 interventions

Trial outcomes

Primary outcomes

Number of patients who consented to biobanking

The number of patients who agree to be in the Biobanking part of the study and have leftover tumor tissue and some normal blood, bone marrow, or other tissue saved for future research.

Time frame

Baseline

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Children's Oncology Group

Lead sponsor

National Cancer Institute (NCI)

Collaborator

Source ClinicalTrials.gov

Apply now